ArticleDiscover oncology2025
The mediating factors between systemic lupus erythematosus and prostate cancer risk: a two-step Mendelian randomization and transcriptome analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPrevious studies indicate an inverse association between systemic lupus erythematosus (SLE) and prostate cancer (PCa) risk. However, the underlying pathways remain unclear. Therefore, this study aims to elucidate the potential pathways through which SLE influences PCa and explore therapeutic targets.
methodsFirst, we performed two-sample Mendelian randomization (MR) to confirm the causal relationship between SLE and PCa risk, followed by a two-step MR analysis to evaluate the mediation effects of immune cell characteristics and sex hormone levels. Next, comprehensive sensitivity analyses were conducted to ensure robustness, including heterogeneity testing, pleiotropy assessment, and leave-one-out validation. Then, we integrated transcriptomic data from SLE and PCa using weighted gene co-expression network analysis (WGCNA) to identify shared driver genes. Finally, we explored potential PCa therapeutic targets through: (1) summary-data-based MR (SMR), (2) colocalization analysis, and (3) phenome-wide association studies (PheWAS).
resultThe MR analysis indicated that SLE was associated with reduced PCa risk. Further, the two-step MR analysis showed that two sex hormones (total testosterone, bioavailable testosterone) and four immune-cell characteristics (IgD + CD24 + B cell %B cell, activated & resting CD4 regulatory T cell absolute count, CD3 on terminally differentiated CD8 + T cell, and HLA DR on myeloid dendritic cell) could partially explain the protective effect of SLE on PCa. Additionally, we identified 48 shared driver genes involved in immune regulation-related biological processes. Ultimately, the SMR analysis and co-localization studies supported TOR1B as a potential therapeutic target for PCa.
conclusionOur study once again emphasizes the protective effect of SLE on PCa and confirms the mediating role of sex hormone and immune-cells, and highlights TOR1B as a potential therapeutic target for PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.